Antivenin-associated serum sickness in a dog.
anatomy
anesthesiology
cardiovascular
coagulation
fluid balance
Journal
Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
ISSN: 1476-4431
Titre abrégé: J Vet Emerg Crit Care (San Antonio)
Pays: United States
ID NLM: 101152804
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
21
04
2017
revised:
24
08
2017
accepted:
06
09
2017
pubmed:
27
8
2019
medline:
18
12
2019
entrez:
27
8
2019
Statut:
ppublish
Résumé
To describe a case of documented serum sickness in a dog following administration of a single dose of a novel antivenin crotalidae polyvalent. A 4-year-old female neutered mixed breed dog developed recurrent signs of hypersensitivity (swelling, edema, urticaria/hives, gastrointestinal signs, vasculitis) at 1 and 2 weeks following administration of a single unit of a novel antivenin crotalidae polyvalent plasma product. Both episodes were treated with antihistamines and glucocorticoids and signs improved rapidly, with a prolonged course of glucocorticoids and antihistamines administered following the second occurrence. Diagnosis of serum sickness was based on clinical appearance of delayed hypersensitivity following exposure to novel biologic product, absence of other inciting cause of hypersensitivity, complement testing, and skin biopsies confirming vasculitis. This case documents the first report of delayed hypersensitivity with a novel antivenin plasma product. This is the only case report of serum sickness to a single unit of antivenin. Additionally, the dog developed recurrence of hypersensitivity following the initial episode at 1 week; appropriate identification and prolonged treatment could have prevented recurrence and additional hospitalization. Cost and benefit analysis should be considered with antivenin administration.
Substances chimiques
Antivenins
0
Crotalid Venoms
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
558-563Informations de copyright
© Veterinary Emergency and Critical Care Society 2019.
Références
Peterson ME. Snake bite: pit vipers. Clin Tech Small Anim Pract. 2006;21:174-182.
Gilliam L, Brunker J. North American snake envenomation in the dog and cat. Vet Clin North Am Small Anim Pract. 2011;41:1239-1259.
Seifer SA, Boyer LV, Benson BE, et al. AAPCC database characterization of native US venomous snake exposures, 2001-2005. Clin Toxicol (Phila). 2009;47:327-335.
Armentano R, Schaer M. Overview and controversies in the medical management of pit viper envenomation in the dog. J Vet Emerg Crit Care. 2011;21(5):461-470.
Najman L, Seshadri R. Rattlesnake envenomation. Compendium Contin Educ Vet. 2007;29:166-176.
Berdoulay P, Schaer M, Starr J. Serum sickness in a dog associated with antivenin therapy for snake bite caused by Crotalus adamanteus. J Vet Emerg Crit Care. 2005;15:206-212.
Juckett G, Hancox JG. Venomous snakebites in the United States: management review and update. Am Fam Physician. 2002;65:1367-1374.
Dart R, Seifer SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (Ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161:2030-2036.
LoVecchio F, Klemens J, Roundy EB, Klemens A. Serum sickness following administration of antivenin (crotalidae) polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ Med. 2003;14:220-221.
Dart R, McNally J. Efficacy, safety, and use of snake antivenom in the United States. Ann Emerg Med. 2001;37:181-188.
Bush S, Ruha AM, Seifert SA, et al. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol (Phila). 2015;53,37-45.
McCown J, Cooke KL, Hanel RM, Jones GL, Hill R. Effect of antivenin dose on outcome from crotalid envenomation: 218 dogs (1988-2006). J Vet Emerg Crit Care. 2009;19:603-610.
Wiley J, Schaer M. Eastern diamondback rattlesnake (Crotalus adamanteus) envenomation of dogs: 31 Cases (1982-2002). J Am Anim Hosp Assoc. 2005;41:22-23.
Schaer M. Eastern diamondback rattlesnake envenomation of 20 dogs. Compend Contin Educ Vet. 1984;6:997-1007.
Witsil A, Wells RJ, Woods C, Rao S. 272 Cases of rattlesnake envenomation in dogs: demographics and treatment including safety of F(ab’)2 antivenom use in 236 patients. Toxicon. 2015;105:19-26.
Murphy K. Janeway's Immunobiology, 8th ed. New York, NY: Garland Science; 2012.
Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781-1790.
Rattler Antivenin Product Label, MgBiologics.com, Ames, IA.
Woods C, Young D. Clinical safety evaluation of F(ab’)2 antivenom (Crotalus durissus-Bothrops asper) administration in dogs. J Vet Emerg Crit Care. 2011;21:565-569.
Katzenbach J, Foy D. Retrospective evaluation of the effect of antivenom administration on hospitalization duration and treatment cost for dogs envenomated by Crotalus viridis: 113 dogs (2004-2012). J Vet Emerg Crit Care. 2015;25:655-659.
Schaer M, Buckley GJ, Conner BJ. Severe pit viper envenomation with extended clinical signs and treatment complications in a dog. J Am Anim Hosp Assoc. 2015;51:329-337.
Tizzard IA. Veterinary Immunology. 7th ed. Philadelphia, PA: Saunders; 2004:335-337.
Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness: a prospective analysis of 35 patients treated with equine antithymocyte globulin for bone marrow failure. Medicine. 1988; 67:40-57.